Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib Plus Chemotherapy in Advanced NSCLC
NCT03636685Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Aug 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03636685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03636685.